video Play video Using Artificial Intelligence to revolutionise drug discovery and development Jackie Hunter, CEO BenevolentBio shares her thoughts on how Artificial Intelligence is accelerating drug discovery DRUG DISCOVERY , ARTIFICIAL INTELLIGENCE , BENEVOLENTBIO , JACKIE HUNTER
video Play video CNBC - Healthcare transformation led by AI BenevolentBio CEO Jackie Hunter speaks about how artificial intelligence has application in health care. DRUG DISCOVERY , ARTIFICIAL INTELLIGENCE , HEALTHCARE
video Play video Hot Topics interviews Ken Mulvany, Founder of BenevolentAI Ken Mulvany, Founder, BenevolentAI, is interviewed by Hot Topics on BenevolentAI as a company and the challenge we are trying to solve. The interview includes how we are helping researchers to access and make sense of the enormous amount of data now available to them. DRUG DISCOVERY , ARTIFICIAL INTELLIGENCE , SCIENCE , KEN MULVANY
video Play video Looking into the Future of Science Innovation Jackie Hunter, CEO BenevolentBio gave an interview to Innovation Forum and participated to a panel on how start-up-industry collaborations can be successfully initiated and maintained to drive innovation. DRUG DISCOVERY , ARTIFICIAL INTELLIGENCE , JACKIE HUNTER , BENEVOLENTBIO , INNOVATION
video Play video FUTUREPROOF Episode Three, Part One Matt Gooderick looks at the potential for the use of artificial intelligence in the health sector, including initiatives by IBM Watson, BenevolentAI and Babylon. DRUG DISCOVERY , ARTIFICIAL INTELLIGENCE , JACKIE HUNTER
video Play video BenevolentAI on BBC Business Live Listen to Kenneth Mulvany, CEO BenevolentAI discussing AI in Medicine at BBC Business Live DRUG DISCOVERY , ARTIFICIAL INTELLIGENCE , KEN MULVANY , BENEVOLENTAI
video Play video Jackie Hunter speaking at The House of Lords Professor Jackie Hunter, CEO, BenevolentBio, gave evidence at The House of Lords Science and Technology Select Committee SCIENCE , TECH , WOODFORD INVESTMENT MANAGEMENT , BENEVOLENTBIO
video Play video Ken Mulvany talks to CNBC at Goldman Sachs’ Disruptive Technology Symposium Listen to our founder Ken Mulvany discussing BenevolentAI's work on artificial intelligence applied to drug discovery. ARTIFICIAL INTELLIGENCE , KEN MULVANY , DISRUPTIVE
video Play video Jérôme Pesenti, CEO BenevolentTech at Project Juno AI Showcase Jérôme Pesenti introduces BenevolentAI's work on applying artificial intelligence to improve scientific discoveries ARTIFICIAL INTELLIGENCE , DRUG DISCOVERY , BENEVOLENTTECH , JEROME PESENTI
video Play video Jackie Hunter @ TechCrunch Disrupt London 2016 DRUG DISCOVERY , ARTIFICIAL INTELLIGENCE , TECHCRUNCH DISRUPT
video Play video Ken Mulvany discusses AI, machine learning and the need to build morality into the technology ARTIFICIAL INTELLIGENCE , MACHINE LEARNING , KEN MULVANY , BENEVOLENTAI , MEDIA , AI PREDICTIONS
video Play video BenevolentAI – Accelerating Scientific Discovery With AI BenevolentAI team explains why the use of DGX-1 will help them in their daily work ARTIFICIAL INTELLIGENCE , DRUG DISCOVERY , UK , DGX-1 , NVIDIA , SUPERCOMPUTER
video Play video NVIDIA DGX-1 - Unboxing at BenevolentAI DEEP LEARNING , NVIDIA , DGX-1 , ARTIFICIAL INTELLIGENCE , SUPERCOMPUTER
video Play video BenevolentAI London Office by the team at BenevolentAI ARTIFICIAL INTELLIGENCE , FUN TIME
